<
AI
Automation
Science
Innovation
Open Source
Blockchain
Social Media
Startups
Culture
Cloud
>

qz
Hims & Hers will get to sell Ozempic. Like, real Ozempic. The stock soars 50%

Novo Nordisk and Hims had clashed on and off for months as the telehealth firm marketed compounded versions of Novo's blockbuster GLP-1 drug Wegovy [...]

Discover Copy
Rating

Innovation

Pricing

Technology

Usability

We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.

Destination
Hims & Hers makes a big Europe push with an acquisition. Knockoff weight loss drugs could be next

Hims & Hers (HIMS) is expanding its playbook across the Atlantic — the U.S.-based telehealth company announced Tuesday that it will acquire European telehealth platform Zava. The acquisition gro [...]

Match Score: 169.58

Destination
Hims & Hers stock slipped as investors were left unimpressed with its new weight-loss drug options

Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that left investors unimpressed.Read more... [...]

Match Score: 154.89

Destination
Hims & Hers strikes a deal with Novo Nordisk to sell Wegovy — and the stock soars 28%

Telehealth company Hims & Hers (HIMS) announced Tuesday that it will begin selling Novo Nordisk’s (NVO) blockbuster weight loss drug Wegovy.Read more... [...]

Match Score: 141.17

Destination
Hims & Hers stock tumbles as the FDA issues a warning about 'unapproved' weight loss drugs

Hims & Hers (HIMS), the millennial-skewed telehealth company, saw its stock tumble nearly 9% on Tuesday, as the company braces for big regulatory shifts in the weight-loss drug industry.Read more. [...]

Match Score: 120.75

Destination
Engadget Podcast: iPhone 16e review and Amazon's AI-powered Alexa+

The keyword for the iPhone 16e seems to be "compromise." In this episode, Devindra chats with Cherlynn about her iPhone 16e review and try to figure out who this phone is actually for. Also, [...]

Match Score: 120.01

Destination
Hims & Hers, Zealand, and Roche fall: Why weight loss drug stocks are down today

Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 market — which is projected to hit $105 billion by 2030, according to Morgan S [...]

Match Score: 73.34

qz
Hims & Hers stock jumps 14% after FDA schedules peptide compounding review

The FDA will convene an outside panel in July to weigh compounding eligibility for 7 peptides, a category Hims & Hers has been positioning to enter [...]

Match Score: 71.02

Destination
Hims and Hers reveal cyberattack — customer support system hacked and personal info stolen, here's what we know

At least 500 people were affected in breach at Hims and Hers. [...]

Match Score: 67.17

qz
Hims & Hers Advances a Consumer-Centric Digital Health Platform

HIMS is broadening its digital-first platform with Labs, hormone therapy and weight-loss programs as it scales personalized care globally. [...]

Match Score: 56.53